Kyverna Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 |
|---|---|---|---|
| Operating income | -$169.8M | -$142.6M | -$62.4M |
| Operating expenses | $169.8M | $142.6M | $62.4M |
| Cash from operations | -$153.7M | -$114.2M | -$52.4M |
| Capital expenditure | $5,000 | $2.2M | $621,000 |
| Free cash flow | -$153.7M | -$116.5M | -$53.0M |
| Impairments | $600,000 | $0 | $0 |
| Total assets | $293.8M | $304.6M | $75.2M |
| Total liabilities | $61.5M | $38.1M | $26.0M |
Shares outstanding 60.8M · Free float 54.0%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.